Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107513
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Providência, Joana | - |
dc.contributor.author | Rodrigues, Tiago M | - |
dc.contributor.author | Oliveira, Mariana | - |
dc.contributor.author | Bernardes, João | - |
dc.contributor.author | Marques, João Pedro | - |
dc.contributor.author | Murta, Joaquim N. | - |
dc.contributor.author | Silva, Rufino | - |
dc.date.accessioned | 2023-07-18T09:19:08Z | - |
dc.date.available | 2023-07-18T09:19:08Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 2314-6133 | pt |
dc.identifier.issn | 2314-6141 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/107513 | - |
dc.description.abstract | Intravitreal injections of antivascular endothelial growth factors have been considered a milestone in the treatment of neovascular age-related macular degeneration (nAMD). However, the increasing incidence of AMD and the burden of visits and injections overcharge both the patient and the healthcare systems. Real-world solutions depend on treatment protocols aimed at optimizing the number of clinical visits while guaranteeing good functional outcomes. We performed a retrospective analysis of 72 eyes from 63 naïve patients diagnosed with nAMD that underwent a fixed intravitreal protocol consisting of bimonthly injections after a three-month loading dose, with either Aflibercept or Ranibizumab (no predefined criteria for treatment selection). Best corrected visual acuity (BCVA) and optical coherence tomography were analyzed at baseline and during follow-up clinical visits (months 3, 6, 12, and 18). From the included participants, 42 followed a fixed regimen with Aflibercept and 30 with Ranibizumab. At the 12-month visit, there was not a statistically significant difference in the mean change of BCVA between the two groups (p=0.121); however, the mean difference in the central retinal thickness was significantly superior in the Aflibercept group (-142.2 versus -51.5, p=0.011). The described fixed regimen seems to be efficient in the treatment of nAMD in a clinical practice setting. | pt |
dc.language.iso | eng | pt |
dc.publisher | Hindawi | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject.mesh | Aged | pt |
dc.subject.mesh | Aged, 80 and over | pt |
dc.subject.mesh | Angiogenesis Inhibitors | pt |
dc.subject.mesh | Female | pt |
dc.subject.mesh | Follow-Up Studies | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Intravitreal Injections | pt |
dc.subject.mesh | Macular Degeneration | pt |
dc.subject.mesh | Male | pt |
dc.subject.mesh | Ranibizumab | pt |
dc.subject.mesh | Receptors, Vascular Endothelial Growth Factor | pt |
dc.subject.mesh | Recombinant Fusion Proteins | pt |
dc.subject.mesh | Retrospective Studies | pt |
dc.subject.mesh | Tomography, Optical Coherence | pt |
dc.subject.mesh | Treatment Outcome | pt |
dc.subject.mesh | Visual Acuity | pt |
dc.title | Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen | pt |
dc.type | article | - |
degois.publication.firstPage | 9276580 | pt |
degois.publication.lastPage | 7 | pt |
degois.publication.title | BioMed Research International | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1155/2018/9276580 | pt |
degois.publication.volume | 2018 | pt |
dc.date.embargo | 2018-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.grantfulltext | open | - |
item.fulltext | Com Texto completo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0002-1014-0483 | - |
crisitem.author.orcid | 0000-0001-8926-5176 | - |
crisitem.author.orcid | 0000-0001-8676-0833 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais I&D IBILI - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
RealWorld-Results-of-Aflibercept-versus-Ranibizumab-for-the-Treatment-of-Exudative-AMD-Using-a-Fixed-RegimenBioMed-Research-International.pdf | 1.75 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License